Rocket Pharmaceuticals Investor Presentation — January 2021

Document content

S E E K I N G G E N E T H E R A P Y C U R E SCorporate Presentation

2Important Information

Cautionary Statement Regarding Forward -Looking Statements

Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation , Rocket's expectations

regarding its guidance for 2020 in light of COVID -19, the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi

Anemia (FA), Leukocyte Adhesion Deficiency -I (LAD -I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and

the safety, effectiveness and timing of related pre -clinical studies and clinical trials, may constitute forward -looking stateme nts for the purposes of the safe

harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subjec t to substantial risks,

uncertainties and assumptions. You should not place reliance on these forward -looking statements, which often include words such as "believe," "expect,"

"anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of suc h terms or the negative of those

terms. Although Rocket believes that the expectations reflected in the forward -looking statements are reasonable, Rocket cannot guarantee such

outcomes. Actual results may differ materially from those indicated by these forward -looking statements as a result of various i mportant factors, including,

without limitation, Rocket's ability to monitor the impact of COVID -19 on its business operations and take steps to ensure the s afety of patients, families

and employees, the interest from patients and families for participation in each of Rocket’s ongoing trials, our expectations regarding when clinical trial

sites will resume normal business operations, our expectations regarding the delays and impact of COVID -19 on clinical sites, pa tient enrollment, trial

timelines and data readouts, our expectations regarding our drug supply for our ongoing and anticipated trials, actions of re gulatory agencies, which may

affect the initiation, timing and progress of pre -clinical studies and clinical trials of its product candidates, Rocket's depen dence on third parties for

development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as

those risks more fully discussed in the section entitled "Risk Factors" in Rocket’s Quarterly Report on Form 10 -Q for the quarte r ended September 30,

2020, filed November 6, 2020 with the SEC. Accordingly, you should not place undue reliance on these forward -looking statements. All such statements